Additional New GlycoMark® Test and SGLT-2 Inhibitor Clinical Data To Be Presented at the ADA Advancing Precision Diabetes Medicine Symposium

Posted on October 7, 2019 by

New York, NY (October 7, 2019) — GlycoMark, Inc. announces additional study data describing GlycoMark® test results in patients on SGLT-2 inhibitors are being presented during the American Diabetes Association (ADA) Advancing Precision Diabetes Medicine Research Symposium on October 8 – 9, 2019 in Madrid, Spain.  The GlycoMark test, an FDA-cleared and CE marked blood test used…
Read More